Form 4: Nautilus Biotechnology Director Michael Altman Acquires 45,000 Stock Options

Director Michael Seth Altman reports acquisition of 45,000 stock options in Nautilus Biotechnology, Inc.

Summary

• Michael Seth Altman, a director of Nautilus Biotechnology, Inc., filed a Form 4 disclosing a transaction.
• On June 14, 2024, Altman acquired 45,000 stock options with an exercise price of $2.56.
• These options vest monthly over a year, contingent upon Altman's continuous service as a 'Service Provider' as defined in the Issuer's 2021 Equity Incentive Plan.
• The options expire on June 14, 2034.
• Following the transaction, Altman directly owns 45,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director can be seen as a sign of confidence, but it's a routine transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities. This filing indicates changes in the beneficial ownership of securities by a company's directors.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates